Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Dutasteride and Oxandrolone Interaction: Avoid | Peptide Database

Compound Profiles Dutasteride Dual 5-Alpha Reductase Inhibitor | Hair Loss & BPH Dutasteride competitively inhibits both the Type I and Type II isoforms of the enzyme 5-alpha reductase. Type II is the predominant isoform in the prostate and hair follicles, whi

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Dutasteride

Dual 5-Alpha Reductase Inhibitor | Hair Loss & BPH

Dutasteride competitively inhibits both the Type I and Type II isoforms of the enzyme 5-alpha reductase. Type II is the predominant isoform in the prostate and hair follicles, while Type I is found primarily in the skin, sebaceous glands, and liver.

Oxandrolone

Oral Anabolic Steroid | Lean Mass & Recovery

Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tissue. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, which means it does not cause estrogen-mediated water retention or gynecomastia.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Dutasteride with Oxandrolone?

Combining Dutasteride with Oxandrolone is not recommended. Both Dutasteride and Oxandrolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Dutasteride and Oxandrolone safe together?

This combination carries significant risk. Both Dutasteride and Oxandrolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Dutasteride and Oxandrolone?

Both Dutasteride and Oxandrolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Dutasteride and Oxandrolone?

Dutasteride has a half-life of ~5 weeks (extremely long; active metabolite accumulation over months) and Oxandrolone has a half-life of ~9-10 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

FDA-approved for treatment of essential hypertension as monotherapy or in combination with other antihypertensives. Provides consistent 24-hour blood pressure reduction. Particularly effective for AAS-induced hypertension where elevated blood pressure is driven by RAAS activation and increased erythropoiesis. FDA-approved for reduction of cardiovascular morbidity in patients at high risk. The ONTARGET trial demonstrated non-inferiority to ramipril for the composite of cardiovascular death, MI, stroke, and hospitalization for heart failure in over 25,000 high-risk patients. Angiotensin II receptor blockade counteracts the pro-hypertrophic and pro-fibrotic effects of supraphysiological androgen levels on the myocardium. Preclinical and observational data support the use of ARBs to attenuate left ventricular hypertrophy in steroid users. Widely recommended in harm reduction protocols. Reduces intraglomerular pressure and proteinuria by blocking angiotensin II-mediated efferent arteriolar constriction. Slows progression of chronic kidney disease, particularly in patients with diabetic nephropathy or hypertensive nephrosclerosis. Relevant for AAS users where elevated blood pressure and NSAID co-use may compromise renal function. Telmisartan's partial PPAR-gamma agonism improves insulin sensitivity without the weight gain associated with full PPAR-gamma agonists like pioglitazone. May reduce the risk of new-onset diabetes in hypertensive patients. The metabolic benefit is particularly relevant for users of compounds that impair glucose tolerance (e.g., growth hormone, trenbolone).

Source: peptide-db.com ↗

Research Indications

Currently in Phase 2 clinical trials for the treatment of androgenetic alopecia. Phase 2a results showed measurable increases in hair count and thickness with the 0.05% topical gel formulation. PP405 directly targets metabolic dormancy in hair follicle stem cells by inhibiting MPC1/MPC2 and promoting anagen re-entry. This mechanism may address follicle miniaturization at an earlier stage than androgen-blocking approaches.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Letrozole is administered orally as a tablet, with approximately 99.9% bioavailability -- essentially complete absorption. Food does not significantly affect absorption. The 2-day half-life supports every-other-day dosing for estrogen management protocols, though bodybuilding doses are dramatically lower than the medical 2.5mg/day breast cancer dose. Tablets are commonly available in 2.5mg strength and can be split or quartered for the lower doses typically used in hormonal optimization. On-cycle estrogen management (conservative) 0.25mg Every other day (EOD) Oral On-cycle estrogen management (moderate) 0.5mg Gynecomastia flare-up (short-term rescue) 0.5-1mg Every other day (EOD) for 1-2 weeks, then taper Breast cancer treatment (medical) 2.5mg Once daily

Source: peptide-db.com ↗
Side effects

Common Side Effects

Severe HDL cholesterol suppression (winstrol is among the worst oral steroids for lipid damage) Significant LDL cholesterol elevation Joint dryness and pain, particularly in knees, shoulders, and elbows (notorious side effect) Hepatic stress with elevated liver enzymes (ALT/AST) Suppression of endogenous testosterone production Hair loss and accelerated male pattern baldness (DHT derivative, particularly harsh on hairline) Acne and oily skin Tendon and ligament stress due to rapid strength gains combined with reduced joint lubrication Dry, painful shin splints during cardiovascular exercise

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →